THE WIRE · № 61206
19.3% Weight Loss at Week 48: Phase Ⅲ Data of Olatorepatide, Hansoh's Dual‑Biased GLP‑1/GIP Agonist, Presented at EASD
01 THE MACHINE READ
WHY IT MATTERS.
A new dual GLP-1/GIP agonist with strong Phase III weight-loss data intensifies competition in the obesity drug market, pressuring incumbents' pricing and share.
Obesity market competition deepens with new entrant data
Regulatory filing and further trial readouts
Data is company-presented, not peer-reviewed
FULL DISPATCH
MILAN, Oct. 2, 2026 /PRNewswire/ -- From September 28 to October 2, 2026, the Annual Meeting of the European Association for the Study of Diabetes (EASD) is being held in Milan, Italy. Hansoh Pharma's self-developed dual-biased glucagon-like peptide-1/glucose-dependent insulinotropic...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs2026-10-02 04:42 UTC
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes2026-09-30 14:15 UTC
Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.2026-09-30 14:32 UTC
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial2026-09-30 14:32 UTC
New Phase 3 trial: A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age — GlaxoSmithKline2026-10-01 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.